newsfilter
← Latest News
Business Wire·

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock– – Cash received supports Precision's expected cash runway through 2028 and strategic focus on in vivo gene editing